Inheritance
Vision & Mission
Strategic Pillars
R&D Pipeline
Global Footprint
Group Structure
Milestones
Founder
Contact Us
EN 简 繁
EN 简 繁
Inheritance
Vision & Mission
Strategic Pillars
R&D Pipeline
Global Footprint
Group Structure
Milestones
Founder
Contact Us
EN 简 繁

Core R&D Programs

The Radiation Protection Platform – Our Scientific Bedrock

•
Research and development of protective solutions against the harmful effects of electromagnetic and nuclear radiation.
•
Serves as the scientific core for our interventions in fatigue and applications in healthy aging.
•
A forward-looking investment in a domain critical to national biosecurity.

Lead Oncology Immunotherapy
Asset – Anti-GDF15 Neutralizing Monoclonal Antibody

•
Status: China Class 1 Innovative Drug.
•
Initial Indication: Targeting immune evasion in hepatocellular carcinoma (Liver Cancer).
•
Significance: Designated as a key innovative drug project by the National Health Commission (NHC). This designation underscores the urgent unmet medical need, as liver cancer currently lacks truly effective pharmaceutical interventions.
•
Platform Potential: While our initial focus is on liver cancer, the GDF-15 pathway is implicated in the immune evasion of multiple tumor types. This positions our antibody as a potential foundational therapy for a broad spectrum of cancers, creating significant long-term value.
•
Approach: A globally synchronized R&D program in this cutting-edge field.
•
In December 2025, the technology transfer agreement was executed to accelerate project industrialization.
•
Listed on the Shanghai Technology Exchange (Listing No.: Z202250159).

Radiation-Resistant Anti-Aging and Anti-Fatigue Health Products

•
Evidence-based formulations derived from our foundational radiation protection research.
•
Designed to enhance physical performance, promote cellular repair mechanisms, and mitigate fatigue.
•
Applicable to a wide demographic, including military personnel, elite athletes, and the general population seeking enhanced vitality.
•
An expanding focus on technologies for healthy aging and longevity.

Leveraging the strategic advantages of Hong Kong's "International Chinese Medicine Hub", we integrate top-tier international and domestic scientific expertise to ensure our R&D output meets and exceeds the highest global standards.